Compare ELTX & KOSS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ELTX | KOSS |
|---|---|---|
| Founded | 2011 | 1953 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Consumer Electronics/Appliances |
| Sector | Health Care | Consumer Staples |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 63.3M | 36.5M |
| IPO Year | 2014 | 1994 |
| Metric | ELTX | KOSS |
|---|---|---|
| Price | $2.36 | $3.55 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $18.00 | N/A |
| AVG Volume (30 Days) | ★ 261.7K | 14.0K |
| Earning Date | 05-12-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 39.29 | ★ 55.56 |
| EPS | N/A | ★ N/A |
| Revenue | $2,301,000.00 | ★ $13,020,773.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 3.14 |
| 52 Week Low | $2.36 | $3.37 |
| 52 Week High | $16.00 | $5.91 |
| Indicator | ELTX | KOSS |
|---|---|---|
| Relative Strength Index (RSI) | 26.74 | 46.18 |
| Support Level | N/A | N/A |
| Resistance Level | $3.32 | $4.10 |
| Average True Range (ATR) | 0.14 | 0.15 |
| MACD | -0.02 | 0.01 |
| Stochastic Oscillator | 3.43 | 55.12 |
Elicio Therapeutics Inc is a clinical-stage biotechnology company advancing novel immunotherapies for the treatment of cancer, including mKRAS-positive pancreatic cancer, colorectal cancer (CRC), lung cancer, and other mKRAS-positive cancers. The Company focuses on developing effective, off-the-shelf immunotherapies using its proprietary Amphiphile (AMP) technology, which aims to enhance the education, activation, and amplification of cancer-specific T cells to promote durable cancer immunosurveillance. Its clinical pipeline includes ELI-002 7P, a lymph node-targeted cancer immunotherapy currently being evaluated in a Phase 2 study for mKRAS pancreatic ductal adenocarcinoma (PDAC), a common form of pancreatic cancer.
Koss Corp is engaged in the design, manufacture, and sale of stereo headphones and related accessory products. It operates in the audio/video industry segment of the home entertainment industry. The company markets a line of headphones, wireless Bluetooth headphones, wireless Bluetooth speakers, computer headsets, telecommunications headsets, and active noise-canceling headphones. The majority of the firm's revenue is derived from sales of stereo headphones. The Company also sells products to distributors for resale to school systems, and directly to other manufacturers for inclusion with their own products.